[HTML][HTML] Vulnerable plaque, characteristics, detection, and potential therapies
A Hafiane - Journal of cardiovascular development and disease, 2019 - mdpi.com
Plaque development and rupture are hallmarks of atherosclerotic vascular disease. Despite
current therapeutic developments, there is an unmet necessity in the prevention of …
current therapeutic developments, there is an unmet necessity in the prevention of …
[HTML][HTML] PCSK9 inhibition: insights from clinical trials and future prospects
JL Katzmann, I Gouni-Berthold, U Laufs - Frontiers in Physiology, 2020 - frontiersin.org
In 2003, clinical observations led to the discovery of the involvement of proprotein
convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies …
convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies …
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
CE Kosmas, D Silverio, J Ovalle… - Patient preference …, 2018 - Taylor & Francis
Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added
to statin therapy it has been shown to cause a significant incremental LDL-C reduction …
to statin therapy it has been shown to cause a significant incremental LDL-C reduction …
Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study
Background The FOURIER (Further Cardiovascular Outcomes Research With PCSK9i
Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors in Subjects With Elevated Risk) …
Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors in Subjects With Elevated Risk) …
[HTML][HTML] Cost-effectiveness analysis of evolocumab for the treatment of dyslipidemia in the Kingdom of Saudi Arabia
A Alghamdi, B Balkhi, A Altowaijri, N Al-Shehri… - PharmacoEconomics …, 2022 - Springer
Background Proprotein convertase subtilisin/kexin type 9 inhibitors, such as evolocumab,
are cholesterol-lowering drugs effective in lowering lipid levels in high-risk patients with …
are cholesterol-lowering drugs effective in lowering lipid levels in high-risk patients with …
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
D Leong, PE Wu - CMAJ, 2019 - Can Med Assoc
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors Page 1 E894 CMAJ | AUGUST
12, 2019 | VOLUME 191 | ISSUE 32 © 2019 Joule Inc. or its licensors 1 Proprotein convertase …
12, 2019 | VOLUME 191 | ISSUE 32 © 2019 Joule Inc. or its licensors 1 Proprotein convertase …
Évaluation pharmacoéconomique des thérapies efficaces et dispendieuses en prévention des maladies cardiovasculaires
F Fanton-Aita - 2021 - papyrus.bib.umontreal.ca
Les maladies cardiovasculaires (MCV) ont une prévalence élevée dans le monde et sont
considérées comme la deuxième cause de mortalité chez la population canadienne. Les …
considérées comme la deuxième cause de mortalité chez la population canadienne. Les …
The efficacy and cost-effectiveness of evolocumab in the prevention of cardiovascular disease
KM Fahey - 2018 - open.bu.edu
Heart disease is the leading cause of death in the United States. Hyperlipidemia is a
predominant risk factor in the development of atherosclerotic cardiovascular disease …
predominant risk factor in the development of atherosclerotic cardiovascular disease …
